{
    "nctId": "NCT03988595",
    "briefTitle": "Exercise Treatment With Standard Therapy for Metastatic Breast Cancer",
    "officialTitle": "Phase 1 Trial of Exercise Treatment With Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Hormone Receptor Positive Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "maximum feasible dose (MFD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)\n* Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression\n* Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)\n* Sedentary (i.e., \\<60 minutes / week of exercise)\n* Age \\>18 years\n* BMI \u2265 18.5\n* Cleared for exercise participation as per screening clearance via PAR-Q+\n* Cleared for study participation as per screening consultation with an MSK Exercise Physiologist\n* Willingness to comply with all study-related procedures\n* Patients with \"treated and stable\" brain lesions of a duration of \u2265 2 months may be enrolled\n\nExclusion Criteria:\n\n* Life expectancy \\<6 months\n* Enrollment onto any other therapeutic investigational study\n* Mental impairment leading to inability to cooperate\n* Concurrent participation in weight loss or other exercise programs",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}